Search
Showing results for "1"
News & Events
Exercise and blood sugar levels - we need you!Young people with Type 1 Diabetes are needed for a new study looking at whether blood sugar levels affect exercise performance.
Research
Association between male genital anomalies and adult male reproductive disorders: a population-based data linkage study spanning more than 40 yearsUndescended testes is associated with an increased risk of testicular cancer and male infertility, and decreased paternity
News & Events
Cholesterol and blood pressure drugs help teens with diabetesThe study involved screening young people to learn more about the development of long-term kidney, eye and cardiovascular complications in adolescents with T1D.
Browse the published work of the Centre's researchers
What would you discover to help a child? At The Kids, our researchers are committed to Type 1 Diabetes research that makes a real difference.
News & Events
ENDIA milestoneAustralia’s biggest study into the causes of type 1 diabetes recently recruited its 1500th and final participant right here in WA.
News & Events
Join our nutrition videosWould you like to help teach others with diabetes? The team at the Rio Tinto Children’s Diabetes Centre are creating nutrition education videos for children and their parents living with type 1 diabetes.
News & Events
Research participation surveyWe recognise that we can learn a lot from our families. This area of research looks at the reasons why families living with diabetes choose whether or not to participate in research.
Research
Resilience and Diabetes 2 (the RAD2 study)Investigators: Anna Hunt, Ashleigh Lin Stress and anxiety are significant problems in children and adolescence with type 1 diabetes. Not only do
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.